Literature DB >> 15197698

Smoking and Parkinson's disease: systematic review of prospective studies.

Mohamed Farouk Allam1, Michael J Campbell, Albert Hofman, Amparo Serrano Del Castillo, Rafael Fernández-Crehuet Navajas.   

Abstract

We estimated the pooled risk of tobacco smoking for Parkinson's disease (PD). Inclusion criteria included systematic searches of MedLine, PsycLIT, Embase, Current Contents, previously published reviews, examination of cited reference sources, and personal contact and discussion with several investigators expert in the field. Published prospective studies on PD and cigarette smoking. When two or more studies were based on an identical study, the study that principally investigated the relationship or the study that was published last was used. Seven prospective studies were carried out between 1959 and 1997, of which six reported risk estimates. Four cohorts were based on standardised mortality rates, which were exclusively of male. Only one study included risk estimates for both males and females separately. The risk of ever smoker was 0.51 (95% confidence interval, 0.43 to 0.61). There was an obvious protective effect of current smoking in the pooled estimate (relative risk, 0.35; 95% CI, 0.26-0.47). Former smokers had lower risk compared with never smokers (relative risk, 0.66; 95% CI, 0.49-0.88). Although our pooled estimates show that smoking is inversely associated with the risk of PD, the four prospective studies that were based on follow-up of mortality of smokers had many limitations. Further studies evaluating the association between smoking and PD in women are strongly needed. Copyright 2004 Movement Disorder Society

Entities:  

Mesh:

Year:  2004        PMID: 15197698     DOI: 10.1002/mds.20029

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  52 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

Review 2.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

3.  Parkinson's disease and other basal ganglia or movement disorders in a large nationwide cohort of Swedish welders.

Authors:  C M Fored; J P Fryzek; L Brandt; G Nise; B Sjögren; J K McLaughlin; W J Blot; A Ekbom
Journal:  Occup Environ Med       Date:  2006-02       Impact factor: 4.402

Review 4.  Mysterious alpha6-containing nAChRs: function, pharmacology, and pathophysiology.

Authors:  Ke-chun Yang; Guo-zhang Jin; Jie Wu
Journal:  Acta Pharmacol Sin       Date:  2009-06       Impact factor: 6.150

5.  Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2008-07-30       Impact factor: 7.853

Review 6.  Preconditioning provides neuroprotection in models of CNS disease: paradigms and clinical significance.

Authors:  R Anne Stetler; Rehana K Leak; Yu Gan; Peiying Li; Feng Zhang; Xiaoming Hu; Zheng Jing; Jun Chen; Michael J Zigmond; Yanqin Gao
Journal:  Prog Neurobiol       Date:  2014-01-02       Impact factor: 11.685

7.  Earlier age of onset in multiple system atrophy with smoking and heavy alcohol use.

Authors:  Lauren Jackson; Elizabeth A Coon; J Eric Ahlskog; James H Bower; Paola Sandroni; Eduardo E Benarroch; Jay N Mandrekar; Phillip A Low; Wolfgang Singer
Journal:  Parkinsonism Relat Disord       Date:  2019-07-17       Impact factor: 4.891

Review 8.  Molecular genetics of addiction and related heritable phenotypes: genome-wide association approaches identify "connectivity constellation" and drug target genes with pleiotropic effects.

Authors:  George R Uhl; Tomas Drgon; Catherine Johnson; Chuan-Yun Li; Carlo Contoreggi; Judith Hess; Daniel Naiman; Qing-Rong Liu
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 9.  The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.

Authors:  Sharon R Grady; Outi Salminen; Duncan C Laverty; Paul Whiteaker; J Michael McIntosh; Allan C Collins; Michael J Marks
Journal:  Biochem Pharmacol       Date:  2007-07-27       Impact factor: 5.858

10.  Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease.

Authors:  Todd L Edwards; William K Scott; Cherylyn Almonte; Amber Burt; Eric H Powell; Gary W Beecham; Liyong Wang; Stephan Züchner; Ioanna Konidari; Gaofeng Wang; Carlos Singer; Fatta Nahab; Burton Scott; Jeffrey M Stajich; Margaret Pericak-Vance; Jonathan Haines; Jeffery M Vance; Eden R Martin
Journal:  Ann Hum Genet       Date:  2010-01-08       Impact factor: 1.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.